{
  "title": "FDA Approves ALS Treatment Despite Questions About Effectiveness",
  "link": "https://www.nytimes.com/2022/09/29/health/als-treatment-relyvrio.html",
  "guid": "https://www.nytimes.com/2022/09/29/health/als-treatment-relyvrio.html",
  "atom:link": "",
  "description": "The drug is safe, and one trial found it may extend survival and slow paralysis in functions like muscle control and speaking. A larger trial will be completed in 2024.",
  "dc:creator": "Pam Belluck",
  "pubDate": "Thu, 29 Sep 2022 21:14:36 +0000",
  "category": [
    "your-feed-science",
    "Clinical Trials",
    "Drugs (Pharmaceuticals)",
    "Amyotrophic Lateral Sclerosis",
    "Amylyx Pharmaceuticals Inc",
    "Food and Drug Administration",
    "United States",
    "your-feed-healthcare",
    "Cohen, Joshua B",
    "Klee, Justin"
  ],
  "media:content": "",
  "media:credit": "Stefani Reynolds for The New York Times",
  "media:description": "The F.D.A.’s headquarters in Silver Spring, Md. Although the agency’s own reviewers said there wasn’t enough evidence that an experimental medication, AMX0035, works for A.L.S, the F.D.A. approved it, citing the drug’s safety and patients’ desperate need for treatments."
}